TKI 258 in Von Hippel-Lindau Syndrome (VHL)

NCT01266070 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Trial met toxicity stopping rule

Conditions

Von Hippel-Lindau Syndrome

Interventions

DRUG: Dovitinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]